Par Drugs & Chemical Intrinsic Value
Par Drugs & Chemical (PAR) median intrinsic value is ₹180.48 from 9 valuation models (range ₹60–₹260), vs current price ₹101.33 — +78.1% upside (Trading Below Calculated Value), margin of safety 43.9%. Analyse PAR FII DII holdings to track promoter, FII and institutional holdings.
PAR Valuation Methods Summary — DCF, Graham Number & P/E
Par Drugs & Chemical intrinsic value across 9 models vs current price ₹101.33 — upside/downside and value range per method. For current market price and key ratios, visit Par Drugs & Chemical share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹259.60 | ₹207.68 - ₹311.52 | +156.2% | EPS: ₹11.80, Sector P/E: 22x |
| Book Value Method | asset | ₹186.67 | ₹168.00 - ₹205.34 | +84.2% | Book Value/Share: ₹93.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹186.67 | ₹168.00 - ₹205.34 | +84.2% | Revenue/Share: ₹93.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹191.67 | ₹172.50 - ₹210.84 | +89.2% | EBITDA: ₹23.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹136.16 | ₹108.93 - ₹163.39 | +34.4% | CF Growth: 7.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹60.33 | ₹54.30 - ₹66.36 | -40.5% | EPS Growth: 6.4%, Fair P/E: 5.1x |
| Growth Adjusted P/E | growth | ₹180.48 | ₹162.43 - ₹198.53 | +78.1% | Revenue Growth: 3.9%, Adj P/E: 15.3x |
| ROE Based Valuation | profitability | ₹150.00 | ₹135.00 - ₹165.00 | +48.0% | ROE: 13.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹157.42 | ₹141.68 - ₹173.16 | +55.4% | EPS: ₹11.80, BVPS: ₹93.33 |
PAR Intrinsic Value vs Market Price — All Valuation Models
Par Drugs & Chemical fair value range ₹60–₹260 vs current market price ₹101.33 across 9 valuation models. Read Par Drugs & Chemical dividend policy for the complete payout history and dividend yield track record.
PAR Intrinsic Value Analysis — Undervalued or Overvalued?
Par Drugs & Chemical median intrinsic value ₹180.48, current price ₹101.33 — Trading Below Calculated Value by 78.1%, margin of safety 43.9%.
What is the intrinsic value of PAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Par Drugs & Chemical (PAR) is ₹180.48 (median value). With the current market price of ₹101.33, this represents a +78.1% variance from our estimated fair value.
The valuation range spans from ₹60.33 to ₹259.60, indicating ₹60.33 - ₹259.60.
Is PAR undervalued or overvalued?
Based on our multi-method analysis, Par Drugs & Chemical (PAR) appears to be trading below calculated value by approximately 78.1%.
PAR Financial Health — Key Ratios vs Industry Benchmarks
Par Drugs & Chemical financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 16.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.87x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PAR Cash Flow Quality — Operating & Free Cash Flow
Par Drugs & Chemical operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹20 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹10 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹12 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |